Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

NCT06176534 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Breast Cancer
Treatment
HR Low/HER2 Negative

Interventions

DRUG: Experimental: chemotheyapy
DRUG: Active Comparator: endocrine therapy

Sponsor

Henan Cancer Hospital